期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 100, 期 2, 页码 131-141出版社
WILEY
DOI: 10.1002/cpt.362
关键词
-
资金
- Austrian Science Fund (FWF) [KLI 480-B30, F 3513-B20]
- European Community's Seventh Framework program [201380]
- Austrian Science Fund (FWF) [KLI480] Funding Source: Austrian Science Fund (FWF)
ABCB1 and ABCG2 work together at the blood-brain barrier (BBB) to limit brain distribution of dual ABCB1/ABCG2 substrates. In this pilot study we used positron emission tomography (PET) to assess brain distribution of two model ABCB1/ABCG2 substrates ([C-11] elacridar and [C-11] tariquidar) in healthy subjects without (c.421CC) or with (c.421CA) the ABCG2 single-nucleotide polymorphism (SNP) c.421C>A. Subjects underwent PET scans under conditions when ABCB1 and ABCG2 were functional and during ABCB1 inhibition with high-dose tariquidar. In contrast to the ABCB1-selective substrate (R)-[C-11] verapamil, [C-11] elacridar and [C-11] tariquidar showed only moderate increases in brain distribution during ABCB1 inhibition. This provides evidence for a functional interplay between ABCB1 and ABCG2 at the human BBB and suggests that both ABCB1 and ABCG2 need to be inhibited to achieve substantial increases in brain distribution of dual ABCB1/ABCG2 substrates. During ABCB1 inhibition c.421CA subjects had significantly higher increases in [C-11] tariquidar brain distribution than c.421CC subjects, pointing to impaired cerebral ABCG2 function.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据